---
layout: default
title: Raloxifene
description: "Raloxifene çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 4 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 143
evidence_level: L5
indication_count: 4
---

# Raloxifene

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>4</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Raloxifeneï¼šå¾éª¨è³ªç–é¬†åˆ°åäºŒæŒ‡è…¸æ½°ç˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Raloxifene å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Raloxifene æ˜¯ä¸€ç¨®é¸æ“‡æ€§é›Œæ¿€ç´ å—é«”èª¿ç¯€åŠ‘ï¼ˆSERMï¼‰ï¼ŒåŸæœ¬ç”¨æ–¼åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**åäºŒæŒ‡è…¸æ½°ç˜ (Duodenal Ulcer)** æœ‰æ•ˆï¼Œä½†ç›®å‰**ç„¡è‡¨åºŠè©¦é©—æˆ–æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é é˜²åŠæ²»ç™‚åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | duodenal ulcer (disease)ã€obsolete susceptibility to ischemic strokeã€hypoalphalipoproteinemiaã€duodenal obstruction |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.72% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 7 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. duodenal ulcer (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.72%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Raloxifene æ˜¯ä¸€ç¨®é¸æ“‡æ€§é›Œæ¿€ç´ å—é«”èª¿ç¯€åŠ‘ï¼ˆSERMï¼‰ï¼Œåœ¨ä¸åŒçµ„ç¹”ä¸­å¯è¡¨ç¾å‡ºé›Œæ¿€ç´ ä¿ƒæ•ˆåŠ‘æˆ–æ‹®æŠ—åŠ‘çš„ä½œç”¨ã€‚åœ¨éª¨çµ„ç¹”ä¸­ï¼Œå®ƒè¡¨ç¾ç‚ºé›Œæ¿€ç´ ä¿ƒæ•ˆåŠ‘ï¼Œæœ‰åŠ©æ–¼ç¶­æŒéª¨å¯†åº¦ï¼›åœ¨ä¹³è…ºçµ„ç¹”ä¸­ï¼Œå®ƒè¡¨ç¾ç‚ºé›Œæ¿€ç´ æ‹®æŠ—åŠ‘ã€‚

é—œæ–¼ raloxifene èˆ‡åäºŒæŒ‡è…¸æ½°ç˜çš„é—œè¯ï¼Œç›®å‰ç¼ºä¹æ˜ç¢ºçš„æ©Ÿè½‰è§£é‡‹ã€‚å¯èƒ½çš„å‡è¨­åŒ…æ‹¬ï¼š
- é›Œæ¿€ç´ å¯èƒ½å°èƒƒè…¸é»è†œæœ‰ä¿è­·ä½œç”¨
- æµè¡Œç—…å­¸ç ”ç©¶é¡¯ç¤ºåœç¶“å¾Œå©¦å¥³æ¶ˆåŒ–æ€§æ½°ç˜çš„ç™¼ç”Ÿç‡å¢åŠ 

ç„¶è€Œï¼Œé€™äº›å‡è¨­å°šæœªç¶“éé©—è­‰ï¼Œç›®å‰ç„¡ä»»ä½•è‡¨åºŠè©¦é©—æˆ–æ–‡ç»ç›´æ¥æ”¯æŒ raloxifene ç”¨æ–¼åäºŒæŒ‡è…¸æ½°ç˜çš„æ²»ç™‚ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

ç›®å‰ç„¡ç›¸é—œæ–‡ç»ã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypoalphalipoproteinemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.65%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.65%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. duodenal obstruction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.64%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.64%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. duodenogastric reflux</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.59%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.59%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬024023è™Ÿ | éˆ£ç©©è†œè¡£éŒ 60æ¯«å…‹ | è†œè¡£éŒ  | é é˜²åŠæ²»ç™‚åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬059774è™Ÿ | æ¨‚éª¨åº·è†œè¡£éŒ 60æ¯«å…‹ | è†œè¡£éŒ  | é é˜²åŠæ²»ç™‚åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬025807è™Ÿ | å¸Œéˆ£è†œè¡£éŒ 60æ¯«å…‹ | è†œè¡£éŒ  | é é˜²åŠæ²»ç™‚åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬059410è™Ÿ | äº”æ´²éª¨é¬†è†œè¡£éŒ 60æ¯«å…‹ | è†œè¡£éŒ  | é é˜²åŠæ²»ç™‚åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡ |

## å®‰å…¨æ€§è€ƒé‡

**è—¥ç‰©äº¤äº’ä½œç”¨ï¼š**
æ ¹æ“š DDInter è³‡æ–™åº«ï¼Œraloxifene èˆ‡å¤šç¨®å¸¸ç”¨è—¥ç‰©å­˜åœ¨æ½›åœ¨äº¤äº’ä½œç”¨ï¼ŒåŒ…æ‹¬ï¼š
- è³ªå­æ³µæŠ‘åˆ¶åŠ‘ï¼ˆPantoprazole, Omeprazole, Lansoprazoleï¼‰
- H2 å—é«”é˜»æ–·åŠ‘ï¼ˆRanitidineï¼‰
- æŠ—æ½°ç˜è—¥ç‰©ï¼ˆSucralfate, Misoprostolï¼‰

é€™äº›äº¤äº’ä½œç”¨çš„è‡¨åºŠæ„ç¾©å°šæœªæ˜ç¢ºï¼Œä½†åœ¨è€ƒæ…®ç”¨æ–¼æ¶ˆåŒ–é“ç–¾ç—…æ™‚éœ€è¦ç‰¹åˆ¥æ³¨æ„ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Heart Diseases** ğŸŸ¡ Moderate
- In studies of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with raloxifene.  The risk-benefit balance should be considered ...

**Hypertriglyceridemia** ğŸŸ¡ Moderate
- In studies of women with a history of marked hypertriglyceridemia (>5.6 mmol/L or >500 mg/dL) in response to treatment with oral estrogen or estrogen plus progestin may develop increased levels of triglycerides when treated with raloxifene.  Women wi...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Raloxifene undergoes extensive first-pass metabolism in the liver.  Following administration of a single oral dose in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL, plasma raloxifene concentrations...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Raloxifene should be used with caution in patients with moderate or severe renal impairment.

**Thromboembolism** ğŸŸ¢ Minor
- The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.  In clinical trials, women treated with raloxifene had ...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
é€™å€‹é æ¸¬å®Œå…¨åŸºæ–¼æ¨¡å‹æ¨æ¸¬ï¼Œæ²’æœ‰ä»»ä½•è‡¨åºŠè©¦é©—æˆ–æ–‡ç»æ”¯æŒã€‚Raloxifene çš„è—¥ç†æ©Ÿè½‰ï¼ˆSERMï¼‰èˆ‡åäºŒæŒ‡è…¸æ½°ç˜çš„æ²»ç™‚ä¹‹é–“ç¼ºä¹æ˜ç¢ºçš„é—œè¯ã€‚åœ¨æ²’æœ‰åŸºç¤ç ”ç©¶æˆ–è‡¨åºŠè­‰æ“šçš„æƒ…æ³ä¸‹ï¼Œä¸å»ºè­°å°‡æ­¤é æ¸¬æ¨é€²åˆ°è‡¨åºŠæ‡‰ç”¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²è¡ŒåŸºç¤ç ”ç©¶æ¢ç´¢é›Œæ¿€ç´ /SERM å°èƒƒè…¸é»è†œçš„ä¿è­·æ©Ÿè½‰
- æµè¡Œç—…å­¸ç ”ç©¶è©•ä¼° raloxifene ä½¿ç”¨è€…çš„æ¶ˆåŒ–æ€§æ½°ç˜ç™¼ç”Ÿç‡
- å‰è‡¨åºŠç ”ç©¶é©—è­‰è—¥ç†æ©Ÿè½‰


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Carisoprodol]({{ "/drugs/carisoprodol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ipilimumab]({{ "/drugs/ipilimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Paclitaxel]({{ "/drugs/paclitaxel/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tofacitinib]({{ "/drugs/tofacitinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Raloxifeneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/raloxifene/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_raloxifene,
  title = {Raloxifeneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/raloxifene/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
